Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Squibb : Sets 2020 Outlook

share with twitter share with LinkedIn share with facebook
02/06/2020 | 07:40am EDT

By Dave Sebastian

Bristol-Myers Squibb Co. (BMY) on Thursday set its financial outlook for 2020 as it reported fourth-quarter loss and higher sales.

The pharmaceutical company expects 2020 revenue of $40.5 billion to $42.5 billion both on a reported and adjusted basis.

It sees earnings of 75 cents a share to 95 cents a share, or $6 a share to $6.20 a share on an adjusted basis.

The company said its guidance for 2020 and 2021 includes the effect of the Celgene acquisition and the Otezla divestiture.

Shares rose 1.1% in premarket trading.

Write to Dave Sebastian at dave.sebastian@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -0.49% 59.14 Delayed Quote.-7.87%
CELGENE 0.10% 108.24 Delayed Quote.68.89%
share with twitter share with LinkedIn share with facebook
Latest news on BRISTOL-MYERS SQUIBB COMPA
07/02BRISTOL-MYERS SQUIBB COMPANY : Ex-dividend day for
FA
06/29BRISTOL MYERS SQUIBB : European Commission Approves Reblozyl for the Treatment o..
AQ
06/29SELLAS Life Sciences Advancing Its Innovative Immunotherapy Across Phase 1, 2..
AQ
06/26BRISTOL MYERS SQUIBB : Immunology & Cardiovascular Presentation
PU
06/26BRISTOL MYERS SQUIBB : Myers, Acceleron Get EU Approval for Reblozyl
DJ
06/26BRISTOL MYERS SQUIBB : European Commission Approves Reblozyl (luspatercept) for ..
BU
06/26MERCK : Intensity Therapeutics Announces Publication of Research Reporting that ..
AQ
06/25BRISTOL MYERS SQUIBB : Investor Series Presentation
PU
06/22BRISTOL MYERS SQUIBB : Early Pipeline & Immuno-Oncology Presentation
PU
06/22BRISTOL MYERS SQUIBB : Supplemental epidemiology information
PU
More news
Financials (USD)
Sales 2020 41 924 M - -
Net income 2020 1 114 M - -
Net Debt 2020 27 686 M - -
P/E ratio 2020 113x
Yield 2020 3,02%
Capitalization 134 B 134 B -
EV / Sales 2019
EV / Sales 2020 3,85x
Nbr of Employees 30 000
Free-Float 77,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 71,14 $
Last Close Price 59,14 $
Spread / Highest target 40,3%
Spread / Average Target 20,3%
Spread / Lowest Target 1,45%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Gerald L. Storch Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-7.87%133 815
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG6.02%299 393
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-9.64%193 542
PFIZER, INC.-11.92%191 697